Payers Say They Likely Will Cover METex14 NSCLC Agents

When the FDA approved Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) in early May, the tablet became the first treatment approved for a specific type of non-small cell lung cancer (NSCLC). Commercial payers have indicated a willingness to cover the drug within the first six months of launch, according to data from Zitter Insights.

The agency gave Tabrecta accelerated approval for the treatment of adults with metastatic NSCLC whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 skipping (METex14) (see story, p. 3). The agency also approved Foundation Medicine, Inc.’s FoundationOne CDx as a companion diagnostic.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

woman-holding-bowel
June 13

Studies Reveal Impact of SonarMD Program on Managing IBD

READ MORE
pills-and-bills
June 13

Report: Led by Anti-Inflammatories, Specialty Drugs Continue Upward Trend

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
June 13

New FDA Approvals: FDA Expanded Mircera’s Patient Population

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today